Misonix and Focus Surgery Announce the Development of Next Generation Sonoblate for Treatment of Benign and Cancerous Prostate Tumors.

FARMINGDALE, NY--(BUSINESS WIRE)--Sept. 23, 1999--

Non-Invasive Treatment May Improve Survival

Rates and Reduce Side-Effects

Misonix Incorporated (Nasdaq: MSON) and Focus Surgery, Inc. today announced the start of the development of Focus Surgery's next generation Sonoblate(TM) ("SBX") platform for the non-invasive treatment of benign and cancerous prostate tumors. Misonix owns 20% of Focus Surgery and is jointly developing the next generation Sonoblate(TM) high intensity focused ultrasound ("HIFU") machines.

An earlier version of the SBX(TM), the Sonoblate 200(TM), has been approved in Japan for the treatment of Benign Prostatic Hyperplasia ("BPH") and over 1,200 patients have been successfully treated. In the U.S., Focus Surgery is conducting Phase III clinical trials for the non-invasive treatment of BPH, commonly known as enlarged prostate. The Company estimates that approximately eight million men have BPH and over $4.5 billion a year is spent on its treatment in the U.S. The worldwide market is estimated to be $8 billion.

Prostate cancer is the second most fatal cancer, after lung cancer, claiming the lives of over 37,000 men in the U.S. and costing approximately $5 billion annually. Focus Surgery is conducting prostate cancer feasibility studies using HIFU in Japan with Hitachi Medical Corporation and Takai Hospital Supply with the support of a Japanese government grant.

Narendra T. Sanghi, President and CEO of Focus Surgery, continued, "We hope to begin manufacturing and marketing the SBX(TM) to treat BPH in the U.S. next year, after the completion of our Phase III trials and the receipt of FDA approval. In the meantime, we continue to research the technology's efficacy for prostate cancer in early stage trials in Japan. We believe that we are at the forefront of prostate disease treatment and will continue our efforts to bring the SBX(TM) to market as soon as possible."

Dr. Martin Resnick, M.D. Chairman of the Department of Urology at Case Western Reserve University said, "HIFU is a new treatment modality that offers much promise for patients with BPH and carcinoma of the prostate. Initial results appear encouraging with patients showing good responses in both symptom relief and minimal complications. We hope this technology will prove to be highly effective for patients with localized prostate cancer and will diminish the occurrence of side effects such as reduced urinary and sexual function which are common with radiation therapy and surgery."

Michael A. McManus, Jr., President and CEO of Misonix, Inc. commented, "Since this is National Prostate Cancer Awareness Week, we feel it is very important to emphasize how proud we are to be contributing to the development of new treatments for prostate disease through our alliance with Focus Surgery. SBX(TM) may dramatically improve the outcomes for BPH and prostate cancer patients and, at the same time, reduce treatment cost through the elimination of expensive disposables and fewer complications after surgery. With SBX(TM) we combine the power of ultrasound guidance and a HIFU beam to produce precise lesions in the diseased prostate, using a single, patented ultrasound transducer, which represents an entirely new technology for urology disease treatment. The beam does not damage intervening healthy tissue or have cumulative post-operative complications."

Misonix, Inc. develops, manufactures, and/or markets medical, scientific, and industrial ultrasonic and air pollution systems.

Focus Surgery, Inc. is a privately-held company that develops, manufactures and markets image-guided, non-invasive surgical equipment using high intensity focused ultrasound, a technology capable of destroying deep-seated tissue by rapidly elevating the temperature in the focal zone, without affecting the intervening tissue.

Forward Looking Statements: Statements in this news release looking forward in time are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties, including general economic conditions, delays and risks associated with the performance of contracts, uncertainties as to the results of research and development, potential acquisitions, consumer and industry acceptance, litigation and regulatory risks.